Barriers to the initiation of, and persistence with, insulin therapy

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3105-3112

  Oliveria, Susan A ^a,b,h   Menditto, Laura A ^c   Yood, Marianne Ulcickas ^d,h   Koo, Yuri H ^e   Wells, Karen E ^f   McCarthy, Bruce D ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SANOFI   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g Allina Hospitals & Clinics   (United States)

^h EpiSource   (United States)

Author keywords

Alternative routes of insulin; Barriers; Outcomes; Patient experience; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; COMPREHENSION; CONFERENCE PAPER; DIABETIC PATIENT; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; INJECTION; INSULIN TREATMENT; INTERVENTION STUDY; INTERVIEW; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACY; PHYSICIAN; PRESCRIPTION; SELF REPORT; TELEPHONE; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENTS;

EID: 37749054852     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242638     Document Type: Conference Paper

References (17)

1. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847-53
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-32
3. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 2002;18:S21-S26
4. Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care 2003;9(Suppl):S63-S80
5. American Diabetes Association. Clinical practice recommendations 1999. Diabetes Care 1999;22(Suppl 1):S1-S114
6. 1c test results. J Gen Intern Med [in press]
7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335-42
8. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
9. Wright A, Burden AC, Paisley RB, et al.; for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
10. Snoek FJ. Breaking the barriers to optimal glycaemic control - what physicians need to know from patients' perspectives. Int J Clin Pract Suppl 2002;129:80-4
11. An analysis of insulin conversion patterns and treatment duration in enrollees with Type II diabetes. Eden Prairie (MN): Ingenix Pharmaceutical Services; 2002
12. Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001;51:665-72
13. Mollema ED, Snoek FJ, Heine RJ, van der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabetic Med 2001;18:671-4
14. Berlin I, Bisserbe JC, Eiber R, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care 1997;20:176-8
15. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-46
16. Musey VC, Lee JK, Crawford R, et al. Diabetes in urban African-Americans. I. Cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis. Diabetes Care 1995;18:483-9
17. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 281;21:2005-12